Venus Remedies Limited

NSEI:VENUSREM Stock Report

Market Cap: ₹4.2b

Venus Remedies Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Venus Remedies.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth17.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17
Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14
Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13
Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14
Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Oct 31
Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Jun 03
Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Jul 15
Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

May 31
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30
I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24
Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01
Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16
Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11
Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14
We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23
Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22
Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Venus Remedies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:VENUSREM - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20246,146221442653N/A
6/30/20246,149285N/AN/AN/A
3/31/20246,014285238373N/A
12/31/20235,619290N/AN/AN/A
9/30/20235,35425567150N/A
6/30/20235,076209N/AN/AN/A
3/31/20235,555266288366N/A
12/31/20225,418157N/AN/AN/A
9/30/20225,492181230329N/A
6/30/20226,119359N/AN/AN/A
3/31/20226,002407274411N/A
12/31/20215,702756N/AN/AN/A
9/30/20215,684816809681N/A
6/30/20215,087715N/AN/AN/A
3/31/20215,4816181,2411,318N/A
12/31/20205,320213N/AN/AN/A
9/30/20204,939871,1561,196N/A
6/30/20204,586-40N/AN/AN/A
3/31/20203,407-100698776N/A
12/31/20193,490-161N/AN/AN/A
9/30/20193,281-269506596N/A
6/30/20193,286-269N/AN/AN/A
3/31/20193,219-286354453N/A
3/31/20183,724-307N/A312N/A
3/31/20174,000-171N/A589N/A
3/31/20164,18317N/A469N/A
3/31/20154,64052N/A678N/A
3/31/20145,416643N/A526N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VENUSREM's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if VENUSREM's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if VENUSREM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if VENUSREM's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if VENUSREM's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VENUSREM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 15:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Venus Remedies Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ashish KushwahaFirstCall Research
Nagaraju AirruvaFirstCall Research